Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 3/2014

01-09-2014 | Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies

Authors: Tong Dai, MD, PhD, Elizabeta Popa, MD, Manish A. Shah, MD

Published in: Current Treatment Options in Oncology | Issue 3/2014

Login to get access

Opinion statement

Cancers of the upper gastrointestinal tract form a prevalent and highly morbid group of malignancies. Specifically, median survival for patients with esophagus, gastric, and pancreatic cancers is less than 1 year, and although there has been progress in therapeutic strategies, the vast majority of newly diagnosed patients with these cancers will die of their disease. 18F-FDG PET (18f-fluorodeoxyglucose positron emission tomography) is a useful but underutilized resource for identifying metastatic disease in the upper gastrointestinal tract. While prevalent in the United States, worldwide, 18F-FDG PET is underutilized especially in countries with a growing emergence of gastroesophageal cancers, despite evidence of clear benefit in cancer staging, and in some cases response assessment and surveillance.
Literature
1.
Kim JW, Gao P, Dang CV. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 2007;26(2):291–8.PubMedCrossRef
2.
Favaro E, Nardo G, Persano L, Masiero M, Moserle L, Zamarchi R, et al. Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol. 2008;173(4):1186–201.PubMedCrossRefPubMedCentral
3.
Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111–5.PubMedCrossRef
4.
Shiomi S, Kawabe J. Clinical applications of positron emission tomography in hepatic tumors. Hepatol Res. 2011;41(7):611–7.PubMedCrossRef
5.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
6.
Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005;103(1):148–56.PubMedCrossRef
7.
Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002;94(4):921–8.PubMedCrossRef
8.
Sihvo EI, Rasanen JV, Knuuti MJ, Minn HR, Luostarinen ME, Viljanen T, et al. Adenocarcinoma of the esophagus and the esophagogastric junction: positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease. J Gastrointest Surg. 2004;8(8):988–96.PubMedCrossRef
9.
Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ, Kim SE, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med. 2000;41(5):808–15.PubMed
10.
van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547–57.PubMedCrossRefPubMedCentral
11.
Chatterton BE, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B, et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36(3):354–61.PubMedCrossRef
12.
Torrance AD, Almond LM, Fry J, Wadley MS, Lyburn ID. Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer? Surgeon J R Coll Surg Edinb Irel. 2013.
13.
Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 2005;7(6):422–30.PubMedCrossRef
14.
Heeren PA, Jager PL, Bongaerts F, van Dullemen H, Sluiter W, Plukker JT. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med. 2004;45(6):980–7.PubMed
15.
Lerut T, Flamen P, Ectors N, Van Cutsem E, Peeters M, Hiele M, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg. 2000;232(6):743–52.PubMedCrossRefPubMedCentral
16.
Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18(18):3202–10.PubMed
17.
Bella AJ, Zhang YR, Fan W, Luo KJ, Rong TH, Lin P, et al. Maximum standardized uptake value on PET/CT in preoperative assessment of lymph node metastasis for thoracic esophageal squamous cell carcinoma. Chin J Cancer. 2014.
18.
Kajiwara T, Hiasa Y, Nishina T, Matsumoto T, Hori S, Nadano S, et al. Maximum standardized uptake value in F-fluoro-2-deoxyglucose positron emission tomography is associated with advanced tumor factors in esophageal cancer. Mol Clin Oncol. 2014;2(2):313–21.PubMedPubMedCentral
19.
Chen SH, Chan SC, Chao YK, Yen TC. Detection of synchronous cancers by fluorodeoxyglucose positron emission tomography/computed tomography during primary staging workup for esophageal squamous cell carcinoma in Taiwan. PLoS ONE. 2013;8(11):e82812.PubMedCrossRefPubMedCentral
20.
Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19(12):3058–65.PubMed
21.
Kauppi JT, Oksala N, Salo JA, Helin H, Karhumaki L, Kemppainen J, et al. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol. 2012;51(5):636–44.PubMedCrossRef
22.
Rebollo Aguirre AC, Ramos-Font C, Villegas Portero R, Cook GJ, Llamas Elvira JM, Tabares AR. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature. Ann Surg. 2009;250(2):247–54.PubMedCrossRef
23.
Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, et al. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy. Ann Surg Oncol. 2012;19(5):1678–84.PubMedCrossRef
24.
Metser U, Rashidi F, Moshonov H, Wong R, Knox J, Guindi M, et al. F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer. Ann Nucl Med. 2014.
25.
Teyton P, Metges JP, Atmani A, Jestin-Le Tallec V, Volant A, Visvikis D, et al. Use of positron emission tomography in surgery follow-up of esophageal cancer. J Gastrointest Surg. 2009;13(3):451–8.PubMedCrossRef
26.
Smyth EC, Shah MA. Role of (1)(8)F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol. 2011;17(46):5059–74.PubMedCrossRefPubMedCentral
27.
Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, et al. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115(14):3196–203.PubMedCrossRef
28.
Rizk NP, Tang L, Adusumilli PS, Bains MS, Akhurst TJ, Ilson D, et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol. 2009;4(7):875–9.PubMedCrossRef
29.
Schollaert P, Crott R, Bertrand C, D’Hondt L, Borght TV, Krug B. A systematic review of the predictive value of FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. J Gastrointest Surg. 2014.
30.
Cuenca X, Hennequin C, Hindie E, Rivera S, Vercellino L, Baruch-Hennequin V, et al. Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas. Eur J Nucl Med Mol Imaging. 2013;40(4):477–85.PubMedCrossRef
31.
Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, et al. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using (18)F-fluorodeoxiglucose positron emission tomography ((18)F-FDG-PET). Ann Surg Oncol. 2014;21(2):575–82.PubMedCrossRef
32.
Park JM, Jang YJ, Kim JH, Park SS, Park SH, Kim SJ, et al. Gastric cancer histology: clinicopathologic characteristics and prognostic value. J Surg Oncol. 2008;98(7):520–5.PubMedCrossRef
33.
Kim WS, Kim YY, Jang SJ, Kimm K, Jung MH. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci. 2000;15(4):420–4.PubMedPubMedCentral
34.
Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92(3):634–41.PubMedCrossRef
35.
Mukai K, Ishida Y, Okajima K, Isozaki H, Morimoto T, Nishiyama S. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer. 2006;9(3):192–6.PubMedCrossRef
36.
Li B, Zheng P, Zhu Q, Lin J. Accurate preoperative staging of gastric cancer with combined endoscopic ultrasonography and PET-CT. Tohoku J Exp Med. 2012;228(1):9–16.PubMedCrossRef
37.
Namikawa T, Okabayshi T, Nogami M, Ogawa Y, Kobayashi M, Hanazaki K. Assessment of F-fluorodeoxyglucose positron emission tomography combined with computed tomography in the preoperative management of patients with gastric cancer. Int J Clin Oncol. 2013.
38.
Kim EY, Lee WJ, Choi D, Lee SJ, Choi JY, Kim BT, et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. Eur J Radiol. 2011;79(2):183–8.PubMedCrossRef
39.
Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22.PubMedCrossRef
40.
Smyth E, Schoder H, Strong VE, Capanu M, Kelsen DP, Coit DG, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. 2012.
41.
Jain VK, Cunningham D, Chau I. Preoperative and postoperative chemotherapy for gastric cancer. Surg Oncol Clin N Am. 2012;21(1):99–112.PubMedCrossRef
42.
Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24(29):4692–8.PubMedCrossRef
43.
Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013;24(5):1262–6.PubMedCrossRefPubMedCentral
44.
Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8(9):797–805.PubMedCrossRef
45.
Meyer zum Buschenfelde C, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, et al. 18F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med. 2011;52(8):1189–96.CrossRef
46.
Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, et al. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during neoadjuvant treatment: HICON trial. BMC Cancer. 2011;11:266.PubMedCrossRefPubMedCentral
47.
Wu LM, Hu JN, Hua J, Gu HY, Zhu J, Xu JR. 18 F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2012;27(3):472–80.PubMedCrossRef
48.
Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection: a meta-analysis. Surg Oncol. 2013;22(3):162–6.PubMedCrossRef
49.
Baiocchi GL, Marrelli D, Verlato G, Morgagni P, Giacopuzzi S, Coniglio A, et al. Follow-up after gastrectomy for cancer: an appraisal of the Italian Research Group for Gastric Cancer. Ann Surg Oncol. 2014.
50.
Gong N, Wong CS, Chu YC. Is lymph node metastasis a common feature of gastrointestinal stromal tumor? PET/CT correlation. Clin Nucl Med. 2011;36(8):678–82.PubMedCrossRef
51.
Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.PubMedCrossRef
52.
Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45(3):357–65.PubMed
53.
Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27(3):439–45.PubMedCrossRef
54.
Van den Abbeele AD. The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13 Suppl 2:8–13.PubMedCrossRef
55.
Hahn S, Bauer S, Heusner TA, Ebeling P, Hamami ME, Stahl A, et al. Postoperative FDG-PET/CT staging in GIST: is there a benefit following R0 resection? Eur J Radiol. 2011;80(3):670–4.PubMedCrossRef
56.
John TG, Greig JD, Carter DC, Garden OJ. Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg. 1995;221(2):156–64.PubMedCrossRefPubMedCentral
57.
Orlando LA, Kulasingam SL, Matchar DB. Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther. 2004;20(10):1063–70.PubMedCrossRef
58.
Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—usefulness and limitations in “clinical reality”. Ann Nucl Med. 2003;17(4):261–79.PubMedCrossRef
59.
Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y. FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol. 2013;19(29):4808–17.PubMedCrossRefPubMedCentral
60.
Hu SL, Yang ZY, Zhou ZR, Yu XJ, Ping B, Zhang YJ. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation. Nucl Med Commun. 2013;34(6):533–9.PubMedCrossRef
61.
Matsumoto I, Shirakawa S, Shinzeki M, Asari S, Goto T, Ajiki T, et al. 18-fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(6):712–8.
62.
Baiocchi GL, Bertagna F, Gheza F, Grazioli L, Calanducci D, Giubbini R, et al. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of (18)FDG-PET confirmed. Ann Surg Oncol. 2012.
63.
Hong HS, Yun M, Cho A, Choi JY, Kim MJ, Kim KW, et al. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med. 2010;35(10):776–9.PubMedCrossRef
64.
Lee TY, Kim MH, Park do H, Seo DW, Lee SK, Kim JS, et al. Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol. 2009;193(2):343–8.PubMedCrossRef
65.
Jones MJ, Buchanan AS, Neal CP, Dennison AR, Metcalfe MS, Garcea G. Imaging of indeterminate pancreatic cystic lesions: a systemic review. Pancreatology. 2013;13(4):436–42.PubMedCrossRef
66.
Pery C, Meurette G, Ansquer C, Frampas E, Regenet N. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol. 2010;34(8–9):465–74.PubMedCrossRef
67.
Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40(10):923–9.PubMedCrossRef
68.
Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248(6):1014–22.PubMedCrossRef
69.
Okamoto K, Koyama I, Miyazawa M, Toshimitsu Y, Aikawa M, Okada K, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2011;16(1):39–44.PubMedCrossRef
70.
Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77(5):1420–5.PubMedCrossRef
Metadata
Title
The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies
Authors
Tong Dai, MD, PhD
Elizabeta Popa, MD
Manish A. Shah, MD
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 3/2014
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-014-0301-9

Other articles of this Issue 3/2014

Current Treatment Options in Oncology 3/2014 Go to the issue

Sarcoma (SH Okuno, Section Editor)

Giant Cell Tumor of Bone: Current Treatment Options

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review

Sarcoma (SH Okuno, Section Editor)

Systemic Treatment Options for Radiation-Associated Sarcomas

Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

Molecular Targeted Therapy in Hepatocellular Carcinoma: From Biology to Clinical Practice and Future

Sarcoma (SH Okuno, Section Editor)

Surgical Treatment of Sarcomas of the Spine

Sarcoma (SH Okuno, Section Editor)

GIST Treatment Options after Tyrosine Kinase Inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits